Cantor Fitzgerald, L. P. Poseida Therapeutics, Inc. Transaction History

Cantor Fitzgerald, L. P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.0 - $3.46 $50,000 - $86,500	-25,000 Reduced 33.24%	50,205 $146,000
Q1 2024 May 15, 2024	BUY	$2.76 - $4.13 $69,000 - $103,250	25,000 Added 49.8%	75,205 $239,000
Q4 2023 Feb 14, 2024	BUY	$1.83 - $3.51 $91,875 - $176,219	50,205 New	50,205 $168,000
Q2 2022 Aug 15, 2022	BUY	$1.87 - $5.0 $28,050 - $75,000	15,000 Added 49.66%	45,205 $117,000
Q1 2022 May 16, 2022	BUY	$3.22 - $7.04 $16,100 - $35,200	5,000 Added 19.84%	30,205 $135,000
Q4 2021 Feb 14, 2022	BUY	$6.23 - $7.6 $157,027 - $191,558	25,205 New	25,205 $172,000

38.5M

377K

22.2K

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $237M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

Get notified when there are updates to the investment portfolio of Cantor Fitzgerald, L. P., based on Form 13F filings with the SEC.

Stay updated on Cantor Fitzgerald, L. P. with notifications on news.